Glucose production (GP) is regulated by gluconeogenesis and glycogenolysis. In type 2 diabetes, elevation of GP leads to fasting hyperglycaemia [1] . An elevation of plasma gluconeogenic substrate precursors such as free fatty acids (FFA) or lactate is also seen in type 2 diabetes [2] [3] [4] [5] 
Introduction
Glucose production (GP) is regulated by gluconeogenesis and glycogenolysis. In type 2 diabetes, elevation of GP leads to fasting hyperglycaemia [1] . An elevation of plasma gluconeogenic substrate precursors such as free fatty acids (FFA) or lactate is also seen in type 2 diabetes [2] [3] [4] [5] [6] [7] [8] [9] 
. These findings led to the working hypothesis that elevation of gluconeogenic substrate precursors increases gluconeogenesis and GP. This hypothesis was tested in human beings, dogs and rodents in vivo. The findings as a whole indicate that during the pancreatic clamp, when gluco-regulatory hormones and glucose levels are maintained at basal, intravenous (i.v.) infusion of FFA or lactate increases hepatic gluconeogensis but, contrary to the hypothesis, not GP because of a compensatory inhibition of glycogenolysis

. The underlying 'nutrient-sensing' mechanisms that inhibit glycogenolysis and counteract the direct effects of circulating FFA or lactate on hepatic gluconeogenesis remain to be explored. In this study, we began to assess the underlying nutrient-sensing mechanisms that counteract the direct effect of circulating lactate on hepatic gluconeogenesis in vivo.
The lipid-sensing mechanisms that counteract the direct effect of circulating FFA on hepatic gluconeogenesis have recently been studied [9] . It is demonstrated that the inhibition of hepatic glycogenolysis induced by circulating FFA to restrain GP is mediated by hypothalamic lipid-sensing mechanisms in rodents [9] . The hypothalamic lipid-sensing mechanisms to restrain glycogenolysis and GP are disrupted in diet-induced insulin resistance and obesity, leading to hyperglycaemia in response to systemic lipid infusions [10] . This is in line with previous reports indicating that in [11] .
Unlike the lipid-sensing mechanisms in the body, even in metabolic stress patients with hyperglycaemia, an elevation of circulating lactate still does not increase GP because of an inhibition of glycogenolysis [12] . Consistent with this, in contrast to hypothalamic lipid-sensing mechanisms [13] , activation of central lactate metabolism via direct delivery of lactate into the hypothalamus lowers GP in normal and in early onset of diabetic and obese rodents [14, 15] [14, 16, 17] . One week
Fig. 1 (A) Working hypothesis. The hypothalamic metabolism of lactate to pyruvate and the subsequent activation of the KATP channels are required to maintain glucose homeostasis in response to systemic lactate elevations. Lactate dehydrogenase inhibitor oxamate. KATP channel blocker glibenclamide. (B) Experimental design. Somatostatin (SRIF). During the final 30 min. of the clamps, (C) intravenous lactate infusion elevated plasma lactate levels compared to control (saline, SAL) by ~2-to 2.5-fold. *P Ͻ 0.001 versus SAL. (D) Plasma glucose, (E) plasma insulin, (F) plasma adiponectin and glucagon levels were comparable in all groups during the clamps.
later, catheters were placed in the internal jugular vein and the carotid artery for infusion and sampling during the clamp procedures as previously described [14, 16, 18] 
. Recovery from surgery was monitored by measuring daily food intake and weight gain for 4-5 days after surgery. The study animal protocol was approved by the Institutional Animal Care and Use Committee of the University Health Network.
Clamp procedure in rats
All the rats were restricted to 20 g of food the night before the experiments to ensure the same nutritional status. To groups of conscious unrestrained rats, we infused i.v. sodium L-lactate (100 mol/kg min., pH 7.0) to elevate plasma lactate concentrations by ~2-to 2.5-fold as seen in exercise for 4 hrs (Fig. 1A-C Fig. 2A) in the presence of similar degree of plasma lactate elevation (Fig. 1C) . This decrease in glucose infusion rate was due entirely to an elevation of GP (Fig. 2B) rather than a change in glucose uptake (Fig.  2C) Fig. 2A) in the presence of similar degree of plasma lactate elevation as observed in the other groups (Fig. 1C) . The drop in glucose infusion rate was caused by an increase in GP (Fig. 2B) and not a change in glucose uptake (Fig. 2C) (Fig. 3B-D) . In contrast, MBH OXA administration decreased glucose infusion rate required to maintain euglycaemia in the same degree of plasma lactate elevation (Fig. 3B) . Again, the decrease in glucose infusion rate was due to increased GP (Fig. 3C) , rather than a change in glucose uptake (Fig. 3D) processes [9, 15, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . Specifically, direct activation of either (i) insulin/leptin signalling pathways [19, 21-25, 28, 29] or (ii) lipid/lactate metabolism [9, 15, 30] (Fig. 1E and F) and glucose (Fig. 1D) were maintained near basal levels. Consistent with previous reports in human beings [8] 
Statistical analysis
Statistical analysis was done by ANOVA or unpaired Student's t-test as appropriate. Statistical analysis was accepted as significant with a P-value less than 0.05. Data are presented as means ϩ S.E.M. © 2008 The Authors Journal compilation © 2008 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 2 Central sensing mechanisms of circulating lactate regulate glucose production (GP). In the presence of systemic elevation of lactate, direct inhibition of central lactate metabolism via i.c.v. administration of lactate dehydrogenase inhibitor oxamate (OXA) (compared to control) led to a marked (A) decrease in exogenous glucose infusion rate and (B) increase in GP during the final 30 min. of the clamps. Similarly, direct inhibition of central KATP channels via i.c.v. administration of blocker glibenclamide (A) decreased exogenous glucose infusion rate and (B) increased GP in response to systemic lactate infusions. (C) Glucose utilization
